RVL Pharmaceuticals plc

Good morning, everyone. My name is Todd, and I will be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals first quarter 2023 financial results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star and one on your telephone keypad. As a reminder, this conference call is being recorded today, May 11th, 2023. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for RVL Pharmaceuticals. Please go ahead.

Thank you, Operator. Welcome to RVL Pharmaceuticals' first quarter 2023 financial results and commercial update call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison, Chief Operating Officer, J.D. Schaub, and Principal Accounting Officer, Mike DiPietro. This morning, the company issued a press release detailing financial results for the three-month-ended March 31, 2023. This press release and a webcast of this call can be accessed through the investor section of the RVL website at rvlpharma.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to RVL's management as of today and involve risks and uncertainties, including those noted in today's press release and the company's filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. During this call, we refer to non-GAAP financial measures such as adjusted EBITDA loss. For a reconciliation of adjusted EBITDA loss to net loss, please see the tables at the end of today's press release. The archived webcast of this call will be available for 30 days on RVL's website, rvlpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on Thursday, May 11, 2023. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to RVL's CEO, Brian Markison. Brian Markison Thank you, Lisa.

With the first quarter in the rearview mirror, we are now past the one-year mark in our aesthetic launch, and we remain truly excited about the prospects for UpNIC Brand. Our cash-paid multi-channel strategy is beginning to pay dividends as we leverage the P&L to drive growth. Our eye care business continued to grow, which is remarkable considering that there has been no personal promotion in this sector for over six months. We believe that that is testimony to the efficacy, safety, and ultimately patient satisfaction with the brand. It is also meaningful that there is no competition. When examining our aesthetic progress, we once again see a strong reorder pattern emerge as practices learn how to integrate a novel product into their daily routine. Our sales professionals were heavily focused on helping accounts cycle through inventory during the first quarter and also increased our total new accounts. Later in the call, JD will walk through the specific metrics behind our performance. Telemedicine will also begin to play a meaningful role in our business over time, especially for those patients who do not wish to visit a provider. We are in the early phase of this strategy where our partners are optimizing their approach behind a calculated spend. In the very near future, their advertising should become more prominent. JD will also describe our new e-commerce platform called Elevate, which will open a whole new line of communication with our providers and, most importantly, their patients. Finally, I'd like to add that we reached an agreement on a special protocol assessment, or SPA, with the FDA for our baclofen. We will now ramp up our effort to partner the brand and deliver value for this important asset. And with that, I'd like to turn the call over to Mike for more specifics around our financial performance in the quarter. Mike?